Ocular blood flow is considered an important factor in determining the extent of visual damage occurring in primary open angle glaucoma (POAG). The effect of top ical pilocarpine, a parasympathomimetic vasodilator, on the pulsatile ocular blood flow (POBF) in POAG subjects was studied. A pneumotonometer linked to the Langham Ocular Blood Flow System recorded the intraocular pres sure (lOP) pulse from which POBF was calculated. Measurements were taken from 18 POAG subjects treated with both G pilocarpine and G timolol, 2 weeks after withdrawing G pilocarpine and again 1 week after reinstituting full treatment. Recordings from 20 POAG patients treated with only G timolol were taken as control values. There was no significant difference in the lOP or POBF between the controls and POAG patients on dual therapy. Furthermore when G pilocarpine was tempo rarily withdrawn there was no significant change in POBF despite a significant rise in lOP. The results imply that aqueous pilocarpine has no direct effect on the pulsa tile component of ocular blood. There is some evidence the beta-I-selective blocker, betaxolol, may increase ocular blood flow8 and that there
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Primary open angle glaucoma (POAG) is classically asso ciated with raised intraocular pressure (lOP), glaucoma tous visual field loss and optic disc cupping. To date treatment has been aimed at reducing the lOP to within normal levels. However, despite satisfactory lOP control, some patients continue to show visual deterioration. 1-3
These findings, along with the increasing recognition of normal tension glaucoma, have led many workers in this field to speculate on the importance of ocular blood flow, in particular to the optic nerve head, in the aetiology of glaucoma.4 It is not known conclusively how present treat ments used in glaucoma therapy affect ocular blood flow.
Several authors have found that although timolol, a com monly used non-selective topical beta blocker, is effective in reducing lOP it does not improve ocular blood flow.s-8
There is some evidence the beta-I-selective blocker, betaxolol, may increase ocular blood flow8 and that there Eye(1993)7,S07-S10 is a greater preservation of visual fields in patients treated with betaxolol as opposed to timolo1.9
Pilocarpine, a muscarinic parasympathomimetic, is effective in reducing lOP, but because of its side effects, namely miosis and spasm of accommodation in pre-pres byopic subjects, it has become a second line drug in the treatment of POAG in most centres. The uveal circulation is derived from the posterior ciliary circulation, as is the optic nerve head circulation. It has a dense neural innerv ation in which the parasympathetic system is vasodilatory.
Intra-arterial injections of acetylcholine cause an increase in choroidal blood flow in rabbits and cats,IO.l! and acetyl choline activity has been isolated in the ciliary nerves of primates. 12 Stimulation of the facial nerve, which supplies parasympathetic fibres to the uveal tissue, causes a marked vasodilatation in the choroid in rabbits and monkeys. 13, 14 From this evidence pilocarpine might be expected to reduce vascular resistance and improve ocular perfusion when used in the treatment of glaucoma, and several groups have studied this effect. Animal studies, using the microsphere technique, have failed to show a significant increase in choroidal blood flow after topical pilocar pine.ls-l? In healthy human subjects ocular perfusion pres sures, measured by oculo-oscillo-dynamography, showed a modest increase in systolic ciliary perfusion after topical pilocarpine. 18 Recent pneumotonometer studies have demonstrated a significant increase in the pulsatile com ponent of ocular blood flow after 4% pilocarpine gel, but not after 2% aqueous drops.8
All these studies used pilocarpine in isolation. How ever, as mentioned, it is more usual to prescribe pilo carpine in combination with a beta blocker, when the latter is ineffective on its own and the patient is unsuitable for drainage surgery. The present report studied the effect of chronically administered pilocarpine, given in conjunc tion with topical timolol, on the pulsatile ocular blood flow.
PATIENTS AND METHODS

Patient Selection and Entry
Two groups of glaucoma subjects were recruited from the outpatient department: 18 patients treated with both top ical G pilocarpine and G timolol, and 20 patients treated with G timolol only, these latter subjects acting as con trols. All patients were diagnosed as having POAG, orig inally presenting with a raised lOP (>22 mmHg), glaucomatou� optic disc cupping and visual field loss, and an open iridocomeal angle. Some had had a laser trabecu loplasty but none had undergone intraocular surgery or had another ocular disease. They were all systemically well, no patient was diabetic and no patient was taking systemic medication that could affect ocular blood flow.
Not all patients in the pilocarpine and timolol group were on the same concentraton of G pilocarpine: 7 were on 4%, 3 on 3%, 5 on 2% and 3 on 1 %. All took their eye drops four times a day. In addition all subjects were on G timolol 0.25% twice daily apart from 4 who were taking G timolol 0.5%. The average age of subjects in the pil ocarpine and timolol group was 63.0 years (SO 9.2 years) and their mean refractive error was 0.09 dioptres (SO 0.50 dioptres). All control subjects were taking G timolol 0.25% twice daily; their average age was 63.5 years (SO 11.7 years) and refractive error -0.52 dioptres (SO 1.04 dioptres). There were no significant differences in the ages or refractive errors between the two groups.
Study Design
Ocular blood flow was measured in the supine position after 15 minutes' rest, using a pneumotonometer probe linked to the Langham Ocular Blood Flow System. This technique measures the lOP pulse from which average lOP (diastolic lOP plus half pulse amplitude), pulse amplitude (the difference between systolic and diastolic lOP), heart rate and an estimate of pulsatile ocular blood flow (POBF) and pulse volume (POBF divided by heart rate) were derived as previously described.19,20 Systemic blood pressure was measured with a Takeda autosphyg momanometer and mean blood pressure was defined as diastolic blood pressure plus one third of the pulse pres sure. All measurements were taken in at least duplicate between 0900 and 1800 hours.
Control subjects were measured on one occasion. Sub jects in the pilocarpine and timolol group were measured three times: initially on both medications, 2 weeks after temporarily withdrawing G pilocarpine, and finally 1 week after restarting G pilocarpine. For any one subject K. G. CLARIDGE 
Statistical Analysis
Comparisons between the timolol-only and pilocarpine and timolol groups were made by Student's unpaired t-test for the following parameters: lOP, pulse amplitude, pulse volume, POBF, heart rate and mean blood pressure. Stu dent's paired t-test was used to compare the above para meters in the pilocarpine and timolol group whilst on and off G pilocarpine. Subgroups within the pilocarpine and timolol group according to the strength of G pilocarpine used, were compared by analysis of variance.
RESULTS
Measurements taken from only one eye of each subject were used in the analysis. If both eyes fitted the diagnostic criteria, the eye with the most marked clinical signs was included. For the timolol and pilocarpine group there were no significant differences between the initial set of measurements and those taken after reinstituting treat ment and thus, for clarity, comparisons were made using the former measurements. Table I shows the group means for the measured parameters in the timolol-only group and in the pilocarpine and in timolol group whilst on full treat ment and when G pilocarpine was temporarily withdrawn.
Comparison ofTimolol-Only Group with Pilocarpine and Timolol Group on Full Treatment
No significant differences were found in the correspond ing mean values of the timolol-only group and the pilo carpine and timolol group whilst on full treatment. In particular when G pilocarpine was administered in combi nation with G timolol there was no statistical difference in ocular pulse amplitude, pulse volume or POBF.
Effect of Pilocarpine Treatment
When subjects in the pilocarpine and timolol group tem porarily discontinued G pilocarpine there was a significant rise in IOP (P<0.03). This was accompanied by a small decrease in ocular pulse volume and POBF, but neither of these parameters showed a significant change. There was no accompanying change in systemic blood pressure or heart rate. have shown that untreated glaucoma subjects have lower POBF values than ocular hypertensives and so it might be expected that patients on dual therapy might have more glaucomatous damage and therefore an even lower POBF than patients controlled by a beta blocker alone. By com paring the timolol-only group and the pilocarpine and tim-0101 group when G pilocarpine was withdrawn, although the latter group had a slightly lower mean POBF, the difference was not significant; this indicates there was no statistical difference in the POBF in the two groups even when they were on equivalent treatment regimes, i.e. G timolol only. It might be that 2 weeks was an insufficient washout period for pilocarpine. However, in the group as a whole there was a significant rise in lOP and in all subjects the pupils dilated during the withdrawal period, indicating reduced pilocarpine activity in the anterior segment at least.
Responses of Individual Patients
The 95% confidence intervals indicate much variation between individuals. A 22% difference in POBF between the on and off treatment phases would be required for this study to have a 90% power of detecting a significant (p<0.05) change. In fact the measured difference in POBF was 7%, and the trial would have a power of only 18% to detect such a small change as being significant.
These results are consistent with those of Boles Carenini et al.8 who showed that, after an 8-day washout period, 2' weeks of treatment with G pilocarpine 2% three times a day resulted in an insignificant (20.6%) increase in POBF, in a series of 14 patients (26 eyes). However, these authors found in a smaller series of 6 patients (12 eyes), a signifi cant (54%) increase in POBF after 2 weeks of treatment with pilocarpine gel 4% daily. In order for pilocarpine to have an effect on the ocular vascular resistance it needs to reach the choroidal vessels in adequate concentrations. Change in pulsatile ocular blood flow in individual subjects when on and off pilocarpine treatment. Key words: Glaucoma, Ocular blood flow, Pilocarpine,
